ICCBBA is pleased to announce that the Dr. Sardjito Hospital, a nonprofit teaching hospital in Yogyakarta, Indonesia, and the Safe Blood...

**COMMENTS ARE NOW CLOSED.** The draft document “ISBT 128 Standard Use of Clinical Trials Product Description Codes (PDCs)” is available...

UPDATE: Deadline for applications is December 4th, 2020. Applications are being accepted for positions on the ICCBBA Board of Directors....

Despite the circumstances due to COVID-19, ICCBBA has contingency plans in place to operate effectively.

Open for commentary: "Standard Labeling for Apheresis Collection Products for Sponsor Cellular Therapy Manufacturing"

In response to requests from blood transfusion services in Singapore and the UK ICCBBA has fast-tracked the release of new product descripti

ICCBBA are recruiting a Technical Director to oversee the development and maintenance of the ISBT 128 Standard. The position is...

This tool is intended for auditors to help them assess compliance to ISBT 128 requirements for cellular therapy products. The audit tool...

ICCBBA recognizes the growing need for facilities to be able to differentiate their blood component units that have been tested for the...